Journal article
Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy
Abstract
AIM: The current standard treatment for IgA nephropathy relies on steroid and/or immunosuppressive therapy and angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blocker (ARB). This study examines the benefits and safety of combining valsartan with clopidogrel and leflunomide as a treatment for progressive IgA nephropathy.
METHODS: Patients with primary IgA nephropathy, confirmed by renal biopsy, were recruited for this …
Authors
Cheng G; Liu D; Margetts P; Liu L; Zhao Z; Liu Z; Tang L; Fang Y; Li H; Guo Y
Journal
Nephrology, Vol. 20, No. 2, pp. 77–84
Publisher
Wiley
Publication Date
February 2015
DOI
10.1111/nep.12359
ISSN
1320-5358
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAngiotensin II Type 1 Receptor BlockersBiomarkersChinaClopidogrelCreatinineDisease ProgressionDrug Therapy, CombinationFemaleGlomerular Filtration RateGlomerulonephritis, IGAHumansImmunosuppressive AgentsIsoxazolesKidneyLeflunomideMalePlatelet Aggregation InhibitorsProteinuriaTetrazolesTiclopidineTime FactorsTreatment OutcomeValineValsartan